Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 10, Issue 1 (January 2008) 10, 54–59; 10.1111/j.1745-7262.2008.00368.x

Emerging neuromodulatory molecules for the treatment of neurogenic erectile dysfunction caused by cavernous nerve injury

Anthony J Bella, Guiting Lin, Ilias Cagiannos and Tom F Lue

1.Department of Surgery, Division of Urology, Ottawa Health Research Institute, University of Ottawa, Ottawa K1Y4E9, Canada
2.Department of Neuroscience, Ottawa Health Research Institute, University of Ottawa, Ottawa K1Y4E9, Canada
3.Knuppe Molecular Urology Laboratory, University of California, San Francisco, CA 94143, USA
4.Department of Urology, University of California, San Francisco, CA 94143, USA

Correspondence: Dr Anthony J Bella, The Ottawa Hospital, Civic Campus, B3-Division of Urology, 1053 Carling Avenue, Ottawa K1Y 4E9, Canada. Fax: +1-613-761-5305. E-mail: anthonybella@gmail.com

Advance online publication 1 January 2008

Abstract

Advances in the neurobiology of growth factors, neural development, and prevention of cell death have resulted in a heightened clinical interest for the development of protective and regenerative neuromodulatory strategies for the cavernous nerves (CNs), as therapies for prostate cancer and other pelvic malignancies often result in neuronal damage and debilitating loss of sexual function. Nitric oxide released from the axonal end plates of these nerves within the corpora cavernosa causes relaxation of smooth muscle, initiating the haemodynamic changes of penile erection as well as contributing to maintained tumescence; the loss of CN function is primarily responsible for the development of erectile dysfunction (ED) after pelvic surgery and serves as the primary target for potential neuroprotective or regenerative strategies. Evidence from pre-clinical studies for select neuromodulatory approaches is reviewed, including neurotrophins, glial cell line-derived neurotrophic factors (GDNF), bone morphogenic proteins, immunophilin ligands, erythropoetin (EPO), and stem cells.

Keywords: erectile dysfunction, prostate cancer, radical prostatectomy, postoperative complications, neuroprotection, nerve regeneration, neurotrophins, brain-derived nerve growth factor, immunophilin ligands, stem cells

Full Text | PDF | 中文摘要 |

 
Browse:  1788
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved